Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.

Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC.

Ann Intern Med. 2008 Feb 5;148(3):178-85.

2.

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.

3.

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

Piroth L, Fournel I, Mahy S, Yazdanpanah Y, Rey D, Rabaud C, Faller JP, Hoen B, Fardeheb M, Quantin C, Chavanet P, Binquet C; Groupe InterCOrevih du Nord-Est.

Epidemiol Infect. 2011 Dec;139(12):1835-44. doi: 10.1017/S0950268810002980. Epub 2011 Jan 14.

PMID:
21232172
4.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
5.

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.

Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ.

Arch Intern Med. 2002 Nov 25;162(21):2478-86.

PMID:
12437408
6.

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA.

Ann Intern Med. 2001 Mar 20;134(6):440-50.

PMID:
11255519
7.

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators.

Antivir Ther. 2005;10(1):41-52.

PMID:
15751762
8.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
9.

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators.

Antivir Ther. 2010;15(3):351-61. doi: 10.3851/IMP1542.

10.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

11.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
12.

Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?

Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S, Diero L, Bacon MC, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Jul 30;14:38. doi: 10.1186/1758-2652-14-38.

13.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
14.

Should expectations about the rate of new antiretroviral drug development impact the timing of HIV treatment initiation and expectations about treatment benefits?

Khademi A, Braithwaite RS, Saure D, Schaefer AJ, Nucifora K, Roberts MS.

PLoS One. 2014 Jun 25;9(6):e98354. doi: 10.1371/journal.pone.0098354. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e108643.

15.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
16.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
17.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
18.

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA; Cepac US And Actg A5164 Investigators.

HIV Clin Trials. 2010 Sep-Oct;11(5):248-59. doi: 10.1310/hct1105-248.

19.

Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults.

Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA.

Am J Public Health. 2001 Sep;91(9):1456-63.

20.

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

JAMA. 2001 Nov 28;286(20):2560-7.

PMID:
11722270

Supplemental Content

Support Center